2222756-24-1

Basic information

• Product Name: 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
• CAS NO: 2222756-24-1
• Molecular Weight: 317.12
• Mol File: 2222756-24-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile(2222756-24-1)
• EPA Substance Registry System: 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile(2222756-24-1)

Safety Data

• Hazardous Substances Data: 2222756-24-1(Hazardous Substances Data)

Upstream product

• 2068065-63-2 4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile 
• 351019-18-6 (6-fluoropyridin-3-yl)boronic acid 
• 1207839-91-5 6-bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carbaldehyde 
• 1207557-36-5 6-bromo-4-methoxypyrazolo[1,5-a]pyridine 
• 50720-12-2 3-bromo-5-methoxypyridine 
• 1207836-10-9 6-bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile 
• 444120-95-0 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Downstream Products

• 2152628-33-4 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3.6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 

Relevant articles and documents

Pyrazolo[1,5-a]pyridine compound as well as preparation method and application thereof

The invention relates to pyrazolo[1,5-a]pyridine compounds as shown in a general formula (I) which is described in the specification, and a preparation method, a pharmaceutical composition and application thereof. In the formula, R1, R2, R3, R4, R5, X, Y and Z are as defined in the specification. The pyrazol[1,5-a]pyridine compound provided by the invention can effectively inhibit fusion of a wild type RET, a mutant type RET, especially a G810R mutant type RET, and RET fusion of KIF5B-RET, CCDC6-RET and the like, is good in safety, and can be used for treating RET-mediated diseases, such as cancers and irritable bowel syndromes.

RET inhibitor and pharmaceutical composition and application thereof

The invention belongs to the field of medicines, and relates to an RET inhibitor and a pharmaceutical composition and application thereof. Specifically, the invention relates to a compound as shown in a formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I). The invention also relates to pharmaceutical compositions comprising the compounds, and uses of the compounds and pharmaceutical compositions thereof in the preparation of a medicine which is especially used for the treatment and prevention of RET-related diseases and disorders, including cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.

RET Inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I, and a pharmaceutical composition thereof in the manufacture of a medicament, in particular for the treatment and prophylaxis of diseases and disorders associated and RET.